XXXX cells in @entity2743 before treatment.

@entity1 @entity854 @entity3457 @entity2743
The aim of this study was the @entity854 occurring within T-cell subsets of @entity2743 ' @entity1 before treatment. Special emphasis was placed on the enumeration of activated T cells using a number of new monoclonal antibodies. Lymphocytes from 22 @entity2743 @entity1 were examined. The total number, the percentage of 'helper/inducer' and 'suppressor/cytotoxic' positive cells were evaluated using the antibodies T3, T4 and UCHT4, whereas the cells with killer activity were defined by H25. @entity3457 cells were detected using the antibodies DA6.231, DA6.164, and L243 which bind different epitopes of the beta chains of class II surface antigens and 4F2, which binds a 120,000 molecular weight glycoprotein. The results show no significant change in the total T, helper or suppressor cell phenotype, but an increase in the killer cell percentage was noted. Of those @entity1 tested, 19 of 22 showed an increase in activated T cells, 18 of 22 @entity1 showed a significant increase of T cells bearing class II antigens, 11 of 22 showed an increase of T cells staining with another activated T cell antibody, 4F2. The anti-DR antibodies expressed different binding characteristics, the most striking difference being seen between the antibodies DA6.231 and L243. The results of this study suggest an heterogeneity of the immune response, or differences in activation stage in @entity1 with @entity2743 before therapeutic intervention. An important role for these cells in the pathogenesis of this disorder can be inferred.
